Literature DB >> 29300162

Production of GP64-free virus-like particles from baculovirus-infected insect cells.

Lorena C S Chaves1,2, Bergmann M Ribeiro1, Gary W Blissard2.   

Abstract

The retroviral Gag protein is frequently used to generate 'virus-like particles' (VLPs) for a variety of applications. Retroviral Gag proteins self-assemble and bud at the plasma membrane to form enveloped VLPs that resemble natural retrovirus virions, but contain no viral genome. The baculovirus expression vector system has been used to express high levels of the retroviral Gag protein to produce VLPs. However, VLP preparations produced from baculovirus-infected insect cells typically contain relatively large concentrations of baculovirus budded virus (BV) particles, which are similar in size and density to VLPs, and thus may be difficult to separate when purifying VLPs. Additionally, these enveloped VLPs may have substantial quantities of the baculovirus-encoded GP64 envelope protein in the VLP envelope. Since VLPs are frequently produced for vaccine development, the presence of the GP64 envelope protein in VLPs, and the presence of Autographa californica multicapsid nucleopolyhedrovirus BVs in VLP preparations, is undesirable. In the current studies, we developed a strategy for reducing BVs and eliminating GP64 in the production of VLPs, by expressing the human immunodeficiency virus type 1 gag gene in the absence of the baculovirus gp64 gene. Using a GP64null recombinant baculovirus, we demonstrate Gag-mediated VLP production and an absence of GP64 in VLPs, in the context of reduced BV production. Thus, this approach represents a substantially improved method for producing VLPs in insect cells.

Entities:  

Keywords:  GP64; Gag; HIV-1; baculovirus; virus-like particles

Mesh:

Substances:

Year:  2018        PMID: 29300162     DOI: 10.1099/jgv.0.001002

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Easily purified baculovirus/insect-system-expressed recombinant hepatitis B virus surface antigen fused to the N- or C-terminus of polyhedrin.

Authors:  Leonardo A Silva; Brenda R Camargo; Ana Carolina Araújo; Taylice Leonel Batista; Bergmann M Ribeiro; Daniel M P Ardisson-Araújo
Journal:  Arch Virol       Date:  2021-11-28       Impact factor: 2.574

2.  Development of a simple and high-yielding fed-batch process for the production of porcine circovirus type 2 virus-like particle subunit vaccine.

Authors:  Wenlong Cao; Hui Cao; Xiaoping Yi; Yingping Zhuang
Journal:  AMB Express       Date:  2019-10-11       Impact factor: 3.298

Review 3.  VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.

Authors:  Wasim A Prates-Syed; Lorena C S Chaves; Karin P Crema; Larissa Vuitika; Aline Lira; Nelson Côrtes; Victor Kersten; Francisco E G Guimarães; Mohammad Sadraeian; Fernando L Barroso da Silva; Otávio Cabral-Marques; José A M Barbuto; Momtchilo Russo; Niels O S Câmara; Gustavo Cabral-Miranda
Journal:  Vaccines (Basel)       Date:  2021-11-30

4.  Separation of influenza virus-like particles from baculovirus by polymer-grafted anion exchanger.

Authors:  Katrin Reiter; Patricia Pereira Aguilar; Dominik Grammelhofer; Judith Joseph; Petra Steppert; Alois Jungbauer
Journal:  J Sep Sci       Date:  2020-04-30       Impact factor: 3.645

5.  Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System.

Authors:  Yu Tao; Gaojian Li; Wenqian Zheng; Jianhong Shu; Jian Chen; Fang Yang; Yuehong Wu; Yulong He
Journal:  Int J Mol Sci       Date:  2019-09-09       Impact factor: 5.923

Review 6.  Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases.

Authors:  Hasnat Tariq; Sannia Batool; Saaim Asif; Mohammad Ali; Bilal Haider Abbasi
Journal:  Front Microbiol       Date:  2022-01-03       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.